Opioid-induced endocrinopathy

Journal of the American Osteopathic Association

Volumn 109, Issue 1, 2009, Pages 20-25

  Colameco, Stephen ^a,b   Coren, Joshua S ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; METHADONE; MORPHINE; OPIATE; ORAL CONTRACEPTIVE AGENT; PRASTERONE; TESTOSTERONE;

ADRENAL GLAND; ANDROGEN SYNTHESIS; CHRONIC DISEASE; DIAGNOSTIC TEST; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; HORMONAL THERAPY; HORMONE DEFICIENCY; HUMAN; HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONG TERM CARE; REVIEW; SEXUAL DYSFUNCTION;

EID: 59949093810     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. The Management of Opioid Therapy for Chronic Pain Working Group. VA/DoD Clinical Practice Guideline for the Management of Opioid Therapy for Chronic Pain. Washington, DC: Department of Veteran Affairs; 2003. Available at: http://www.ihs.gov/nonmedicalprograms/nc4/Documents/ ChronicpainguidelinesVA2003.pdf. Accessed November 25, 2008.
2. Luo X, Pietrobon R, Hey L. Patterns and trends in opioid use among individuals with back pain in the United States. Spine. 2004;29:884-890.
3. Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and non- medical use of opioids. Pain Physician. 2008;11(suppl):S63-S88. Available at: http://www.painphysicianjournal.com/linkout-vw.php?issn=1533-3159&vol= 11&page=S63. Accessed December 3, 2008.
4. Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by US primary care physicians from 1992 to 2001. J Pain. 2006:7:225-235.
5. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004;100:851-858. Available at: http://www3. interscience.wiley.com/cgi-bin/fulltext/107061632/HTMLSTART. Accessed November 25, 2008.
6. Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85:221 5-2222. Available at: http://jcem.endojournals.org/cgi/content/full/85/6/2215. Accessed November 25, 2008.
7. Adams ML, Sewing B, Forman JB, Meyer ER, Cicero TJ. Opioid-induced suppression of rat testicular function. J Pharmacol Exp Ther. 1993;266:323-328.
8. Allolio B, Deuss U, Kaulen D, Leonhardt U, Kallabis D, Hamel E, et al. FK 33824, a met-enkephalin analog blocks corticotropin-releasing hormone-induced adrenocorticotropin secretion in normal subjects but not in patients with Cushing's disease. J Clin Endocrinol Metab. 1986;63:1427-1431.
9. Lee C, Ludwig S, Duerksen DR. Low-serum cortisol associated with opioid use: case report and review of the literature. Endocrinologist. 2002;12:5-8.
10. Blank MS, Fabbri A, Catt KJ, Dufau ML. Inhibition of luteinizing hormone release by morphine and endogenous opiates in cultured pituitary cells. Endocrinology. 1986;118:2097-2101.
11. Christo PJ. Opioid effectiveness and side effects in chronic pain [review]. Anesthesiol Clin North America. 2003;21:699-713.
12. Kalyani RR, Gavini S, Dobs AS. Male hypogonadism in systemic disease. Endocrinol Metab Clin North Am. 2007;36;333-348.
13. Taylor T, Dluhy RG, Williams GH. β-endorphin suppresses adrenocorticotropin and cortisol levels in normal human subjects. J Clin Endocrinol Metab. 1983;57:592-596.
14. Finch PM, Roberts LJ, Price L, Hadlow NC, Pullan PT. Hypogonadism in patients treated with intrathecal morphine. Clin J Pain. 2000;16:251-254.
15. Harris JD. Management of expected and unexpected opioid-related side effects. Clin J Pain. 2008;24(suppl 10):S8-S13.
16. Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain [published online ahead of print November 1, 2007]. J Pain. 2008;9:28-36.
17. Mendelson JH, Ellingboe J, Kuehnle JC, Mello NK. Heroin and naltrexone effects on pituitary-gonadal hormones in man: interaction of steroid feedback effects, tolerance and supersensitivity. J Pharmacol Exp Ther. 1980;214:503-506.
18. Santen FJ, Sofsky J, Bilic N, Lippert R. Mechanism of action of narcotics in the production of menstrual dysfunction in women. Fertil Steril. 1975;26:538-548.
19. White PC. Corticosteroid action. In: Becker KL, ed. Principles and Practice of Endocrinology and Metabolism. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:714-719.
20. Daniell HW. DHEAS deficiency during consumption of sustained-action prescribed opioids: evidence for opioid-induced inhibition of adrenal androgen production. J Pain. 2006;7:901-907.
21. Brown RT, Zueldorf M. Opioid substitution with methadone and buprenorphine: sexual dysfunction as a side effect of therapy [review]. Heroin Addict Relat Clin Probl. 2007;9:35-44. Available at: http://www.europad.org/journal/2007/Brown%209(1)2007.pdf. Accessed December 1, 2008.
22. Azizi F, Vagenakis AG, Longcope C, Ingbar SH, Braverman LE. Decreased serum testosterone concentration in male heroin and methadone addicts. Steroids. 1973;22:467-472.
23. Mendelson JH, Meyer RE, Ellingboe J, Mirin SM, McDougle M. Effects of heroin and methadone on plasma cortisol and testosterone. J Pharmacol Exp Ther. 1975;195:296-302.
24. Hanbury R, Cohen M, Stimmel B. Adequacy of sexual performance in men maintained on methadone. Am J Drug Alcohol Abuse. 1977;4:13-20.
25. Cicero TJ, Bell RD, Wiest WG, Allison JH, Polakoski K, Robins E. Function of the male sex organs in heroin and methadone users. N Engl J Med 1975;292:882-887.
26. Brown R, Balousek S, Mundt M, Fleming M. Methadone maintenance and male sexual dysfunction. J Addict Dis. 2005;24:91-106.
27. Goldsmith DS, Hunt DE, Lipton DS, Strug DL. Methadone folklore: beliefs about side effects and their impacts on treatment. Hum Organ. 1984;43:330-340.
28. Mendelson JH, Mendelson JE, Patch VD. Plasma testosterone levels in heroin addiction and during methadone maintenance. J Pharmacol Exp Ther. 1975:192:211-217.
29. Werner AA. The male climacteric: report of two hundred and seventy-three cases. JAMA. 1946;132:188-191.
30. Heller CG, Myers GB. The male climacteric: its symptomatology, diagnosis and treatment. JAMA. 1944;126:472-477.
31. Rissanen J, Hudson R, Ross R. Visceral adipositiy, androgens, and plasma lipids in obese men. Metabolism. 1994;43:1318-1323.
32. Khaw KT, Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol. 1992;2:675-682.
33. Mazer N, Chapman C, Daniell H, Volinn E. Opioid-induced androgen deficiency in men (OPlAD): an estimate of the potential patient population in the US and Canada [abstract]. J Pain. 2004:5(suppl 1):S73. 857. Available at: http://www.genesis.gen.tr/medical4/Actiq/directorcast/DATA/literatur/genel/ overkan.pdf. Accessed December 1, 2008.
34. Daniell HW. Opioid-induced androgen deficiency discussion in opioid contracts. Am J Med. 2006;120:e21.
35. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3:377-384.
36. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society Clinical Practice guideline [published online ahead of print May 23, 2006] [published correction appears in J Clin Endocrinol Metab. 2006;91:2688]. J Clin Endocrinol Metab. 2006;91:1995-2010. Available at: http://jcem.endojournals.org/cgi/content/full/91/6/1995. Accessed December 1, 2008.
37. Wallach J. Introduction to normal values. Interpretation of Diagnostic Tests. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000.
38. Blum J, Hill HR. Diagnosis and treatment of hypogonadism with emphasis on erectile dysfunction and osteoporosis. Prim Care Case Rev. 2003;6:97-109.
39. Steidle CP. New advances in the treatment of hypogonadism in the aging male. Rev Urol. 2003;5(suppl 1):S34-S40.
40. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, et al. Androgen therapy in women: an Endocrine Society clinical practice guideline [published online ahead of print October 3, 2006]. J Clin Endocrinol Metab. 2006;91: 3697-3710. Available at: http://jcem.endojournals.org/cgi/ content/full/91/10/3697. Accessed December 1, 2008.
41. Traish A, Guay AT, Spark RF; Testosterone Therapy in Women Study Group. Are the Endocrine Society's clinical practice guidelines on androgen therapy in women misguided? A commentary. J Sex Med. 2007;4:1223-1234.
42. Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment [review]. Fertil Steril. 2002;77:660-665.
43. Daniell HW, Lentz R, Mazer NA. Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. J Pain. 2006;7:200-210.
44. Daniell HW. Opioid-induced androgen deficiency. Curr Opin Endocrinol Diabetes. 2006;13:262-266.
45. Handelsman DJ, Zajac JD. Androgen deficiency and replacement therapy in men. Med J Aust. 2004;180:529-535. Available at: http://www.mja.com.au/ public/issues/180-10-170504/han10513-fm.html. Accessed December 19, 2008.
46. Brand TC, Canby-Hagino E, Thompson IM. Testosterone replacement therapy and prostate cancer: a word of caution. Curr Urol Rep. 2007;8:185-189.
47. Kingsberg S, Shifren J, Wekselman K, Rodenberg C, Koochaki P, Derogatis L. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. J Sex Med. 2007;4(4 Pt 1):1001-1008.
48. Bolour S, Braunstein G. Testosterone therapy in women: a review. Int J Impot Res. 2005;17:399-408.
49. Palacios S. Advances in hormone replacement therapy: making the menopause manageable. BMC Womens Health. 2008;8:22. Available at: http://www.biomedcentral.com/1472-6874/8/22. Accessed December 23, 2008.
50. Somboonporn W. Testosterone therapy for postmenopausal women: efficacy and safety [review]. Semin Reprod Med. 2006;24:115-124.
51. Schover LR. Androgen therapy for loss of desire in women: is the benefit worth the breast cancer risk [review] [published online ahead of print November 26, 2007]? Fertil Steril. 2008;90:129-140.
52. Estratest and Estratest HS. Physicians' Desk Reference. 62nd ed. Montvale, NJ: Thomson Healthcare; 2008:3125-3129.
53. North American Menopause Society. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society [published online ahead of print September 1, 2005]. Menopause. 2005;12:496-511.
54. Benefits of DHEA: the master hormone. Life Extension Web site. Available at: http://www.lef.org/dhea/benefits-of-dhea.htm. Accessed December 8, 2008.
55. von Mühlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R. Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial [published online ahead of print December 15, 2007]. Osteoporos Int. 2008;19:699-707. Available at: http://www.pubmedcentral.nih.gov/articlerender. fcgi ?tool=pubmed&pubmedid=18084691. Accessed December 1, 2008.
56. Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, et al. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J Clin Endocrinol Metab. 2002;87:4935-4941. Available at: http://jcem.endojournals.org/cgi/content/full/ 87/11/4935. Accessed December 1, 2008.
57. Panjari M, Davis SR. DHEA therapy for women: effect on sexual function and wellbeing [review] [published online ahead of print January 5, 2007]. Hum Reprod Update. 2007;13:239-248. Available at: http://humupd.oxfordjournals. org/cgi/content/full/13/3/239. Accessed December 1, 2008.
58. Gurnell EM, Hunt PJ, Curran SE, Conway CL, Pullenayegum EM, Huppert FA, et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial [published online ahead of print November 13, 2007]. J Clin Endocrinol Metab. 2008;9:400-409.
59. Morales AJ, Haubrich RH, Hwang JY, Asakura H,Yen SS. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf). 1998;49:421-432.
60. Katz N. The impact of opioids on the endocrine system. Pain Manage Rounds. 2005;1(9). Available at http://www.painmanagementrounds.org/crus/ painmgt-09.pdf. Accessed December 1, 2008.
61. Oxycontin, roxicodone, oxycodone forum. Topix Web site. Available at: http://www.topix.com/forum/drug/oxycontin/TN0616VU5R66GUM2C. Accessed January 8, 2009.
62. How come every time I take oxycodone for pain I get a lot of energy? Yahoo! Answers Web site. Available at: http://answers.yahoo.com/question/index? qid=20080630230958AAKFHG9. Accessed January 8, 2009.
63. Why oxycodone? Opiophile Web site. Available at: http://forum.opiophile. org/archive/index.php/t-7834.html. Accessed January 8, 2009.
64. Smith HS. Variations in opioid responsiveness. Pain Physician. 2008;11:237-248. Available at: http://www.painphysicianjournal.com/linkout-vw. php ?issn=1533-3159&vol=11&page=237. Accessed December 19, 2008.
65. Model Policy for the Use of Controlled Substances for the Treatment of Pain. Dallas, Tex: Federation of State Medical Boards of the United States, Inc; 2004. Available at: http://www.fsmb.org/pdf/2004-grpol-Controlled- Substances.pdf. Accessed December 19, 2008.